These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 17924396

  • 41. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.
    Gozes I, Meltzer E, Rubinrout S, Brenneman DE, Fridkin M.
    Endocrinology; 1989 Dec; 125(6):2945-9. PubMed ID: 2583049
    [Abstract] [Full Text] [Related]

  • 42. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.
    Couvineau A, Tan YV, Ceraudo E, Laburthe M.
    Methods Enzymol; 2013 Dec; 520():219-37. PubMed ID: 23332702
    [Abstract] [Full Text] [Related]

  • 43. New nonradioactive technique for vasoactive intestinal peptide-receptor-ligand-binding studies.
    Haberl I, Habringer DS, Andreae F, Artl A, Mosgoeller W.
    Ann N Y Acad Sci; 2006 Jul; 1070():313-6. PubMed ID: 16888184
    [Abstract] [Full Text] [Related]

  • 44. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo.
    Pan CQ, Li F, Tom I, Wang W, Dumas M, Froland W, Yung SL, Li Y, Roczniak S, Claus TH, Wang YJ, Whelan JP.
    J Pharmacol Exp Ther; 2007 Feb; 320(2):900-6. PubMed ID: 17110523
    [Abstract] [Full Text] [Related]

  • 45. Identification and characterization of the prepro-vasoactive intestinal peptide gene from the teleost Paralichthys olivaceus.
    Nam BH, Kim YO, Kong HJ, Kim WJ, Lee SJ, Choi TJ.
    Vet Immunol Immunopathol; 2009 Feb 15; 127(3-4):249-58. PubMed ID: 19084281
    [Abstract] [Full Text] [Related]

  • 46. Structure-activity studies on the vasoactive intestinal peptide pharmacophore. 1. Analogs of tyrosine.
    Bolin DR, Cottrell J, Garippa R, Michalewsky J, Rinaldi N, Simko B, O'Donnell M.
    Int J Pept Protein Res; 1995 Feb 15; 46(3-4):279-89. PubMed ID: 8537181
    [Abstract] [Full Text] [Related]

  • 47. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
    Valiante S, Prisco M, Sciarrillo R, De Falco M, Capaldo A, Gay F, Andreuccetti P, Laforgia V, Varano L.
    J Endocrinol; 2008 Feb 15; 196(2):291-303. PubMed ID: 18252952
    [Abstract] [Full Text] [Related]

  • 48. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.
    Onoue S, Misaka S, Yamada S.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun 15; 377(4-6):579-90. PubMed ID: 18172612
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Novel stable PACAP analogs with potent activity towards the PAC1 receptor.
    Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H, Fournier A.
    Peptides; 2008 Jun 15; 29(6):919-32. PubMed ID: 18353507
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine.
    Onoue S, Ohmori Y, Matsumoto A, Yamada S, Kimura R, Yajima T, Kashimoto K.
    Life Sci; 2004 Feb 06; 74(12):1465-77. PubMed ID: 14729396
    [Abstract] [Full Text] [Related]

  • 55. Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update.
    Muller JM, Debaigt C, Goursaud S, Montoni A, Pineau N, Meunier AC, Janet T.
    Peptides; 2007 Sep 06; 28(9):1655-66. PubMed ID: 17555844
    [Abstract] [Full Text] [Related]

  • 56. PACAP and VIP prevent apoptosis in schwannoma cells.
    Castorina A, Tiralongo A, Giunta S, Carnazza ML, Rasi G, D'Agata V.
    Brain Res; 2008 Nov 19; 1241():29-35. PubMed ID: 18835258
    [Abstract] [Full Text] [Related]

  • 57. Respirable powder formulation of a shortened vasoactive intestinal peptide analog for treatment of airway inflammatory diseases.
    Suzuki H, Mizumoto T, Seto Y, Sato H, Onoue S.
    J Pept Sci; 2018 Mar 19; 24(3):. PubMed ID: 29441631
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.